{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PDS0101",
    "query": {
      "intervention": "PDS0101"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T11:28:43.230Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05232851",
      "title": "A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Human Papillomavirus-Related Carcinoma",
        "Locally Advanced Oropharyngeal Carcinoma",
        "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "FDG-Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-06-16",
      "completion_date": "2026-09-10",
      "has_results": true,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-09-08T11:28:43.230Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05232851"
    },
    {
      "nct_id": "NCT04580771",
      "title": "A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified",
        "Stage IB3 Cervical Cancer FIGO 2018",
        "Stage II Cervical Cancer FIGO 2018",
        "Stage IIA Cervical Cancer FIGO 2018",
        "Stage IIA1 Cervical Cancer FIGO 2018",
        "Stage IIA2 Cervical Cancer FIGO 2018",
        "Stage IIB Cervical Cancer FIGO 2018",
        "Stage III Cervical Cancer FIGO 2018",
        "Stage IIIA Cervical Cancer FIGO 2018",
        "Stage IIIB Cervical Cancer FIGO 2018",
        "Stage IIIC Cervical Cancer FIGO 2018",
        "Stage IIIC1 Cervical Cancer FIGO 2018",
        "Stage IIIC2 Cervical Cancer FIGO 2018",
        "Stage IVA Cervical Cancer FIGO 2018"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2020-10-14",
      "completion_date": "2027-03-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-09-08T11:28:43.230Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04580771"
    },
    {
      "nct_id": "NCT06790966",
      "title": "Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Head and Neck Cancer",
        "Metastatic Head and Neck Cancer",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "Neoplasms, Head and Neck",
        "Unresectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Combination Treatment of PDS0101 and Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Pembrolizumab Monotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "PDS Biotechnology Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-05-30",
      "completion_date": "2026-08-25",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-08T11:28:43.230Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06790966"
    },
    {
      "nct_id": "NCT02065973",
      "title": "An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High-risk HPV Infection and Biopsy-proven CIN1"
      ],
      "interventions": [
        {
          "name": "R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PDS Biotechnology Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 65 Years · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2014-02",
      "completion_date": "2015-12-30",
      "has_results": false,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-09-08T11:28:43.230Z",
      "location_count": 2,
      "location_summary": "Port Jefferson, New York • The Bronx, New York",
      "locations": [
        {
          "city": "Port Jefferson",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065973"
    },
    {
      "nct_id": "NCT04260126",
      "title": "Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Head and Neck Cancer",
        "Recurrent Head and Neck Cancer",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "Neoplasms, Head and Neck"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab (KEYTRUDA®) and PDS0101",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "PDS Biotechnology Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2021-03-29",
      "completion_date": "2025-05-14",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-09-08T11:28:43.230Z",
      "location_count": 18,
      "location_summary": "Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more",
      "locations": [
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04260126"
    },
    {
      "nct_id": "NCT04287868",
      "title": "Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "HPV Cancers",
        "Anal Cancer",
        "Oropharyngeal Cancer",
        "Vulvar, Vaginal, Penile, Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "PDS0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M7824",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NHS-IL12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2020-06-09",
      "completion_date": "2026-05-14",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-08T11:28:43.230Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04287868"
    },
    {
      "nct_id": "NCT07090174",
      "title": "CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HPV Associated Cancers",
        "HIV (Human Immunodeficiency Virus)",
        "Anal Cancer",
        "Cervical Cancer",
        "HPV 16 Infection"
      ],
      "interventions": [
        {
          "name": "PDS0101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-04-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-08T11:28:43.230Z",
      "location_count": 2,
      "location_summary": "New York, New York • The Bronx, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07090174"
    }
  ]
}